12:15 PM EDT, 08/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our target price by $11 to $125, 8.4x our 2026 EPS estimate, a discount to historical due to soft Urolift demand. Q2 EPS of $3.73 vs. $3.42, beat consensus by $0.36. We lift our 2025 EPS forecast to $14.08 from $13.41 and lower 2026's to $14.80 from $15.26. The Interventional segment delivered exceptional 20.4% Y/Y growth to $170M. Several segments faced headwinds, with OEM declining 11.4% Y/Y due to customer inventory management issues, and Interventional Urology dropping 8.1% Y/Y due to persistent UroLift market challenges. TFX completed its acquisition of BIOTRONIK's Vascular Intervention business in early Q3, which we expect to contribute $200M in 2H 2025 and expand TFX's global footprint in the fast-growing peripheral intervention market. Management lifted its 2025 guidance, with adjusted EPS guidance rising to $13.90-$14.30 from $13.20-$13.60, reflecting the BIOTRONIK acquisition. We think TFX will move forward with its current strategy and we expect a separation into two independent publicly traded companies in the coming quarters.